ReviewFrontiers in endocrinology2022
Latent Autoimmune Diabetes in Adults (LADA): From Immunopathogenesis to Immunotherapy.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 38 citations in OpenAlex.
- Searching for LADA in patients with Hashimoto's thyroiditis: A tool for the prevention of LADA.Journal of diabetes investigation · 2026Review
- Proteomic Changes in Patients with LADA-Type Diabetes: Prospects for Diagnostic Biomarkers.International journal of molecular sciences · 2026Review
- Frequency of islet autoantibody seropositivity among adults with newly diagnosed type 2 diabetes in the Kazakh population: A cross-sectional study.Journal of diabetes investigation · 2026Article
- Latent autoimmune diabetes in Saudi adults aged 30-55 years old seen at a tertiary hospital in Riyadh, Saudi Arabia.Journal of family medicine and primary care · 2026Article
- ChatGPT in precision medicine.APL bioengineering · 2026Review
- Current treatment for diabetes: a holistic approach.Hormones (Athens, Greece) · 2026Review
- Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes.JCI insight · 2026Article
- Gut microbiota and the early prevention window in type 1 diabetes and latent autoimmune diabetes in adults: a state-of-the-art narrative review on diet and metabolites.Frontiers in endocrinology · 2026Review
- Explainable machine learning model for in-hospital hypoglycemia risk in patients with latent autoimmune diabetes in adults.Frontiers in immunology · 2026Article
- Analysis of risk factors and establishment of a prediction model for latent autoimmune diabetes in adults.Therapeutic advances in endocrinology and metabolism · 2026Article
- Fulminant and Slowly Progressive Type 1 Diabetes Associated with Pregnancy.International journal of molecular sciences · 2025Review
- Severe tolvaptan-associated hyperglycemia: a case report.Journal of medical case reports · 2025Article
- Vitamin D and Type 2 Diabetes Mellitus: Molecular Mechanisms and Clinical Implications-A Narrative Review.International journal of molecular sciences · 2025Review
- Alcohol Consumption and Autoimmune Diseases.International journal of molecular sciences · 2025Review
- Latent autoimmune diabetes in youth.Frontiers in immunology · 2025Review
- Positive Islet Cell Cytoplasmic Antibody and Long-Term Use of Lipid-Lowering Agents Are Positively Correlated With Peripheral Atherosclerosis in Patients With Autoimmune Diabetes: A Cross-Sectional Study.Journal of diabetes research · 2025Article
- Phenome-Wide Association Study of Latent Autoimmune Diabetes from a Southern Mexican Population Implicates rs7305229 with Plasmatic Anti-Glutamic Acid Decarboxylase Autoantibody (GADA) Levels.International journal of molecular sciences · 2024Article
- Comprehensive alpha, beta, and delta cell transcriptomics reveal an association of cellular aging with MHC class I upregulation.Molecular metabolism · 2024Article
- MiR-144-5p and miR-21-5p do not drive bone disease in a mouse model of type 1 diabetes mellitus.JBMR plus · 2024Article
- A novel subpopulation of monocytes with a strong interferon signature indicated by SIGLEC-1 is present in patients with in recent-onset type 1 diabetes.Diabetologia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latent autoimmune diabetes in adults (LADA) is a type of diabetes characterized by slow autoimmune damage of pancreatic β cells without insulin treatment in the early clinical stage. There are differences between LADA and classical type 1 diabetes (T1D) and type 2 diabetes (T2D) in genetic background, autoimmune response, rate of islet function decline, clinical metabolic characteristics, and so on. The disease progression and drug response of patients with LADA are closely related to the level of islet autoimmunity, thus exploring the pathogenesis of LADA is of great significance for its prevention and treatment. Previous studies reported that adaptive immunity and innate immunity play a critical role in the etiology of LADA. Recent studies have shown that the intestinal microbiota which impacts host immunity hugely, participates in the pathogenesis of LADA. In addition, the progression of autoimmune pancreatic β cell destruction in LADA is slower than in classical T1D, providing a wider window of opportunities for intervention. Therefore, therapies including antidiabetic drugs with immune-regulation effects and immunomodulators could contribute to promising interventions for LADA. We also shed light on potential interventions targeting the gut microbiota and gut-associated immunity, which may be envisaged to halt or delay the process of autoimmunity in LADA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.